Elexacaftor/tezacaftor/ivacaftor (ETI) is a modulator therapy which works by increasing the activity of the malfunctioning CFTR, correcting the underlying CF defect and improving clinical outcomes.8 Here, CFTR is linked to cystic fibrosis.